Literature DB >> 12028409

Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma.

Yasuhiro Ito1, Tsutomu Takeda, Yo Sasaki, Masato Sakon, Terumasa Yamada, Shingo Ishiguro, Shingi Imaoka, Masahiko Tsujimoto, Morito Monden, Nariaki Matsuura.   

Abstract

BACKGROUND: Evaluation of the biological character of carcinomas requires understanding of cell cycle regulators. P57 (Kip2) belongs to the Cip/Kip family and is known to be one of the universal negative regulators of cell cycle.
METHODS: In the present study, therefore, we investigated p57 expression in 37 extrahepatic bile duct carcinomas (BDC) and 28 intrahepatic cholangiocellular carcinomas (CCC).
RESULTS: The average p57 labeling index (LI) in BDC and CCC were 60.8 +/- 7.9 and 58.6 +/- 18.6, respectively, which were significantly lower (p = 0.0008 and p = 0.0408, respectively) than those in normal duct epithelia (73.1 +/- 7.9, 70.4 +/- 8.2). p57 LI was significantly lower in BDC and CCC cases with biological aggressive phenotypes such as poor differentiation (p = 0.0260 and p = 0.0069), lymph node metastasis (p = 0.0274 and p = 0.0214), high Ki-67 LI (p = 0.0164 and p = 0.0343) and cyclin D1 overexpression (p = 0.0359 and p = 0.0255).
CONCLUSION: These findings suggest that decreased p57 expression is related to the increased activity of cell proliferation and also the progression of these carcinomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12028409     DOI: 10.1034/j.1600-0676.2002.01532.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  7 in total

1.  Inactivation of RASSF1A, the tumor suppressor gene at 3p21.3 in extrahepatic cholangiocarcinoma.

Authors:  Yong-Jun Chen; Qi-Bin Tang; Shen-Quan Zou
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

2.  Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice.

Authors:  Xiaoling Xu; Shogo Kobayashi; Wenhui Qiao; Cuiling Li; Cuiying Xiao; Svetlana Radaeva; Bangyan Stiles; Rui-Hong Wang; Nobuya Ohara; Tadashi Yoshino; Derek LeRoith; Michael S Torbenson; Gregory J Gores; Hong Wu; Bin Gao; Chu-Xia Deng
Journal:  J Clin Invest       Date:  2006-06-08       Impact factor: 14.808

3.  Expression of cell cycle regulator p57kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study.

Authors:  Hui Yue; Hui-Yong Jiang
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

4.  Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma.

Authors:  Ke-Jun Nan; Hui Guo; Zhi-Ping Ruan; Zhao Jing; Shaan-Xi Liu
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

5.  Expression of p57kip2, Rb protein and PCNA and their relationships with clinicopathology in human pancreatic cancer.

Authors:  Hui Yue; Yan-Li Na; Xin-Li Feng; Shu-Ren Ma; Fu-Lin Song; Bo Yang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

6.  Increased cyclin D1 expression in cancer of the ampulla of Vater: relevance to nuclear beta catenin accumulation and k-ras gene mutation.

Authors:  K Yamazaki; K Hanami; T Nagao; A Asoh; I Sugano; Y Ishida
Journal:  Mol Pathol       Date:  2003-12

7.  Correlation of CA19-9 and P57 (KiP2) Expression with Tumor Grade and Invasive Front in Oral Squamous Cell Carcinoma.

Authors:  Fatemeh Mashhadiabbas; Moones Rajabi; Mohammad Javad KharaziFard; Hamidreza Moslemi
Journal:  J Dent (Shiraz)       Date:  2018-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.